Tonix Pharmaceuticals (TNXP) News
NASDAQ: TNXPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.38-0.17 (-6.67%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TNXP news summary
We found 8 recent headlines mentioning Tonix Pharmaceuticals (TNXP): 0 in the past week and 7 in the past 30 days, most often from GlobeNewswire, Nasdaq. TNXP is making an outsized move today, down 6.67% at $2.38, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Tonix Pharmaceuticals (TNXP) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Tonix Pharmaceuticals headlines
- Tonix Pharmaceuticals (TNXP) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Tonix Pharmaceuticals Holding Corp. Reports Third Quarter 2026 Financial ResultsTonix Pharmaceuticals Holding Corp. reported net product revenue of approximately $17.2 million for the third quarter of 2026, compared to $3.3 million for the same period in 2025. Net revenue from…Nasdaq
- Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational HighlightsThird quarter TONMYA ® net sales of approximately $15 million, up 37% from the second quarterGlobeNewswire
- Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation ConferenceBERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical…GlobeNewswire
- Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on PainTONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studiesGlobeNewswire
- Canaccord Genuity Initiates Coverage of Tonix Pharmaceuticals Holding with BuyFintel reports that on October 26, 2026, Canaccord Genuity initiated coverage of Tonix Pharmaceuticals Holding (NASDAQGS:TNXP) (DB:TPM0) with a Buy recommendation.Prior to this rating action, the…Nasdaq
- Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company,…GlobeNewswire
- Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical…GlobeNewswire